Erbitux adds 5 weeks to lung cancer survival (Reuters)

[riky]

Erbitux adds 5 weeks to lung cancer survival
    (Reuters)

 


Reuters - Lung cancer patients treated in a large
clinical trial with ImClone Systems Inc's Erbitux and
chemotherapy lived about five weeks longer than patients
treated with chemotherapy alone, according to study results
released on Saturday.


You are not allowed to view links. Register or Login/news.yahoo.com/s/nm/20080531/hl_nm/cancer_lung_erbitux_dc